BioBridgeX
Log inCompare quotes
Indication

Women's Health CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Women's Health drug development covers contraception, endometriosis, fibroids, menopause, PCOS, preeclampsia, and gynecologic oncology. Buyers outsource discovery, hormone and reproductive pharmacology, relevant in vivo models, GLP toxicology including DART, and clinical trials run under GCP in women-only or sex-specific populations. On BioBridgeX you source and compare qualified CRO and CDMO vendors as a neutral vendor of record, free for buyers, under one contract.

Women's Health CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Women's Health CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does a Women's Health program need?

Women's Health is less a single indication than a cluster of them: hormonal and non-hormonal contraception, endometriosis, uterine fibroids, PCOS, menopause and vasomotor symptoms, heavy menstrual bleeding, infertility, preeclampsia and other obstetric conditions, vulvovaginal and pelvic disorders, and gynecologic oncology. The biology runs across small molecules, peptides, hormones and hormone modulators, biologics, and devices, so the CRO and CDMO work a program buys depends heavily on which condition and which modality you are chasing. A GnRH antagonist for fibroids and an antibody for preeclampsia share almost no preclinical menu.

On the discovery side, the recurring theme is endocrine and reproductive pharmacology: estrogen, progesterone, and androgen receptor work, GnRH and gonadotropin signaling, steroidogenesis, and the assays that report on those pathways cleanly. Programs often need receptor binding and functional panels, tissue-specific selectivity reads (you want activity in the endometrium without the off-target endometrial or breast liability), and PK that accounts for the strong sex differences in metabolism that show up once a compound is dosed. Hormone-driven indications also lean on relevant in vivo models, which can be the rate-limiting capability to source: surgically induced or genetically engineered endometriosis models, uterine fibroid xenografts, ovariectomized models for menopause and bone endpoints, and pregnancy or preeclampsia models that comparatively few labs run well.

Preclinical and IND-enabling work in this area carries one weight other therapeutic areas can defer: reproductive and developmental toxicology, the DART package (fertility, embryo-fetal development, and pre- and postnatal development). For a drug aimed at women of reproductive age, DART is not an afterthought, it is central to the safety story and to whether you can enroll women of childbearing potential in early trials. Clinically, the work runs under GCP like any program, but the operational specifics matter: recruiting women-only or sex-specific populations, endpoints that are often patient-reported (pain, bleeding diaries, symptom scales) and need validated instruments, gynecologic imaging and procedures at sites, and in obstetric trials the rare and carefully governed setting of studying drugs in pregnant participants. Vendors that have actually run endometriosis pain trials or contraceptive efficacy studies behave very differently from generalists who have not.

How do you choose a CRO for Women's Health?

Start with fit to the specific condition and modality, not the size of the logo. A CRO that is strong in contraceptive efficacy trials may have never touched a preeclampsia program, and a hormonal-pharmacology discovery shop is the wrong call for a gynecologic-oncology biologic. Ask for relevant case studies in your exact indication and ask whether the people you would actually work with have done that kind of study before. Then run two or three candidates against the same written scope so you are comparing like for like.

  • Therapeutic-area experience: real Women's Health programs finished in your condition (endometriosis, fibroids, menopause, contraception, PCOS, gynecologic oncology), not adjacent work repackaged in a pitch.
  • Relevant disease models or patient access: for preclinical, the specific in vivo model already validated in-house with historical control data; for clinical, demonstrated ability to recruit the women-only or sex-specific population in your geographies, including obstetric or perimenopausal cohorts that are slow to enroll.
  • Reproductive and endocrine depth: hormone receptor and reproductive-pharmacology assays, sex-difference-aware PK, and a DART-capable GLP partner, since reproductive toxicology usually sits on the critical path for a drug used in women of childbearing potential.
  • Regulatory track record: a clean FDA, EMA, or other agency inspection history and experience with the endpoints regulators expect in your indication (contraceptive Pearl Index, bleeding and pain instruments, bone or vasomotor endpoints), plus familiarity with pregnancy-exposure and registry expectations where relevant.
  • Data quality and standards: validated patient-reported outcome instruments, clean bioanalytical methods that detect your compound at the concentration you care about, and CDISC-conformant data delivery so the package holds up at submission.
  • Capacity and turnaround: real availability rather than a booked-solid slot, honest milestone timelines, and a clear change-order policy, because gynecology and obstetric trials are enrollment-driven and amendments are common.

Frequently asked questions

What counts as a Women's Health indication for sourcing a CRO?
It is a broad group rather than one disease. The common ones are contraception (hormonal and non-hormonal), endometriosis, uterine fibroids, PCOS, menopause and vasomotor symptoms, heavy menstrual bleeding, infertility, preeclampsia and other obstetric conditions, vulvovaginal and pelvic disorders, and gynecologic cancers. Because the biology spans hormones, small molecules, peptides, biologics, and devices, the right CRO depends on both the specific condition and the modality. Filter for a vendor that has run programs in your exact indication, not Women's Health in general.
Do Women's Health drugs need reproductive and developmental toxicology (DART)?
Almost always, and earlier than teams expect. DART covers fertility, embryo-fetal development, and pre- and postnatal development, and for a drug intended for women of reproductive age it is central to the safety package, not optional. The timing depends on your trial population and region: the US allows enrolling women of childbearing potential in tightly monitored early Phase 1 with preliminary data, while the EU generally expects embryo-fetal development data first. Settle DART scope and timing with the agency at your pre-IND meeting before you commit budget, and line up a GLP DART CRO early because it often sits on the critical path.
How do I find a CRO with the right preclinical model for endometriosis or fibroids?
This is frequently the hardest capability to source, so make it a screening question rather than a hope. Ask whether the lab already runs the specific model (a surgically induced or genetically engineered endometriosis model, a uterine fibroid xenograft, an ovariectomized menopause model) and whether they have historical control data on it, rather than standing one up for the first time on your program. A validated, in-house model with a track record beats a cheaper quote from a lab learning it on your dollar. On BioBridgeX you can filter by therapeutic area and modality to shortlist vendors with relevant preclinical experience.
What is different about running clinical trials in Women's Health?
The trials run under GCP like any program, but the operational realities are distinct. Recruitment is sex-specific and sometimes narrow (perimenopausal, postpartum, or actively trying to conceive), endpoints are often patient-reported and need validated instruments (pain and bleeding diaries, symptom scales, the contraceptive Pearl Index), and sites need gynecologic imaging and procedures. Obstetric trials add the carefully governed setting of studying drugs during pregnancy, with ethics and monitoring requirements that not every CRO has handled. Prioritize vendors with demonstrated recruitment in your population and experience with the endpoints your regulator expects.
How much does BioBridgeX cost the buyer?
Sourcing on BioBridgeX is free for buyers. Vendors pay a flat 2% platform fee on a pay-when-paid basis, so the prices you compare are not padded with buyer-side markups. Because BioBridgeX is a neutral vendor of record and runs no lab of its own, it has no incentive to steer your contraception, endometriosis, or gynecologic-oncology work toward a preferred site. Coverage spans all indications and modalities across the full lifecycle, so the same account carries forward as your program advances.
Can BioBridgeX coordinate several Women's Health vendors under one contract?
Yes. A single program might pull in a reproductive-pharmacology discovery group, a CRO with the right in vivo model, a GLP DART lab, and a clinical CRO that can recruit your gynecology population. Contracting and paying each separately is the friction. Through BioBridgeX you sign one contract, raise one purchase order, and receive one invoice across every vendor, with BioBridgeX acting as the vendor of record and keeping the strongest provider for each piece of work.

Source Women's Health work with one contract

Compare transparent quotes from qualified Women's Health CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes